1 August 2025 in Cancer Research Communications
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort (n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression (P = 0.2). In urothelial carcinoma (n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.
12 February 2026 in bioRxiv
Circulating tumor DNA (ctDNA) profiling from liquid biopsies is increasingly adopted as a minimally invasive solution for clinical cancer diagnostic applications. Current methods for inferring gene expression from ctDNA require specialized assays or ultra-deep, targeted sequencing, which preclude transcriptome-wide profiling at single-gene resolution. Herein we jointly introduce Triton, a tool for comprehensive fragmentomic and nucleosome profiling of cell-free DNA (cfDNA), and Proteus, a multi-modal deep learning framework for predicting single gene expression, using standard depth (∼30-120x) whole genome sequencing of cfDNA. By synthesizing fragmentation and inferred nucleosome positioning patterns in the promoter and gene body from Triton, Proteus reproduced expression profiles using pure ctDNA from patient-derived xenografts (PDX) with an accuracy similar to RNA-Seq technical replicates. Applying Proteus to cfDNA from four patient cohorts with matched tumor RNA-Seq, we show that the model accurately predicted the expression of specific prognostic and phenotype markers and therapeutic targets. As an analog to RNA-Seq, we further confirmed the immediate applicability of Proteus to existing tools through accurate prediction of gene pathway enrichment scores. Our results demonstrate the potential clinical utility of Triton and Proteus as non-invasive tools for precision oncology applications such as cancer monitoring and therapeutic guidance. Subjects: Circulating tumor DNA, liquid biopsies, patient-derived xenografts, whole genome sequencing, deep learning, convolutional neural network, gene expression